G T Ho

Summary

Publications

  1. ncbi The use of adalimumab in the management of refractory Crohn's disease
    G T Ho
    Gastrointestinal Unit, Western General Hospital, Edinburgh, UK
    Aliment Pharmacol Ther 27:308-15. 2008
  2. ncbi ABCB1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach
    G T Ho
    Molecular Medicine Unit and Gastrointestinal Unit, University of Edinburgh, Western General Hospital, Edinburgh, UK
    Hum Mol Genet 15:797-805. 2006
  3. ncbi The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort
    G T Ho
    Gastrointestinal Unit, Western General Hospital, Edinburgh, UK
    Aliment Pharmacol Ther 24:319-30. 2006
  4. ncbi Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis
    G T Ho
    Western General Hospital, University of Edinburgh, UK
    Am J Gastroenterol 104:673-8. 2009
  5. ncbi Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008)
    G T Ho
    Scottish Society of Gastroenterology, Edinburgh, UK
    Aliment Pharmacol Ther 29:527-34. 2009
  6. ncbi A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis
    C W Lees
    Gastrointestinal Unit, Western General Hospital, Edinburgh, UK
    Aliment Pharmacol Ther 26:411-9. 2007
  7. ncbi Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease?
    G T Ho
    University Department of Medical Sciences, Western General Hospital, Edinburgh, UK
    Gut 52:759-66. 2003
  8. ncbi Regional variation in gene expression in the healthy colon is dysregulated in ulcerative colitis
    C L Noble
    Gastrointestinal Unit, Molecular Medicine Centre, Western General Hospital, Edinburgh, EH4 2XU, UK
    Gut 57:1398-405. 2008
  9. ncbi The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up
    C W Lees
    Gastrointestinal Unit, Western General Hospital, Edinburgh, UK
    Aliment Pharmacol Ther 29:286-97. 2009
  10. ncbi Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery
    G T Ho
    University Department of Gastroenterology, Western General Hospital, Edinburgh EH4 2XU, Scotland, UK
    Aliment Pharmacol Ther 19:1079-87. 2004

Detail Information

Publications13

  1. ncbi The use of adalimumab in the management of refractory Crohn's disease
    G T Ho
    Gastrointestinal Unit, Western General Hospital, Edinburgh, UK
    Aliment Pharmacol Ther 27:308-15. 2008
    ..Adalimumab is a humanized monoclonal antibody targeting tumour necrosis factor-alpha. Recent clinical trials have demonstrated its efficacy in Crohn's disease; however, experience in clinical practice remains limited...
  2. ncbi ABCB1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach
    G T Ho
    Molecular Medicine Unit and Gastrointestinal Unit, University of Edinburgh, Western General Hospital, Edinburgh, UK
    Hum Mol Genet 15:797-805. 2006
    ..In addition, these findings have potentially important implications in the application of pharmacogenetics across a range of common diseases, including HIV, epilepsy and colorectal cancer...
  3. ncbi The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort
    G T Ho
    Gastrointestinal Unit, Western General Hospital, Edinburgh, UK
    Aliment Pharmacol Ther 24:319-30. 2006
    ..Corticosteroids remain the mainstay of first-line therapy in active inflammatory bowel disease...
  4. ncbi Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis
    G T Ho
    Western General Hospital, University of Edinburgh, UK
    Am J Gastroenterol 104:673-8. 2009
    ..We aim to investigate fecal calprotectin (FC) as a biomarker in predicting the clinical course of acute severe ulcerative colitis (ASUC)...
  5. ncbi Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008)
    G T Ho
    Scottish Society of Gastroenterology, Edinburgh, UK
    Aliment Pharmacol Ther 29:527-34. 2009
    ..Adalimumab is a second generation humanized anti-tumour necrosis factor (TNF) monoclonal antibody with established efficacy in Crohn's disease (CD)...
  6. ncbi A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis
    C W Lees
    Gastrointestinal Unit, Western General Hospital, Edinburgh, UK
    Aliment Pharmacol Ther 26:411-9. 2007
    ..A recent controlled trial has suggested that infliximab may be effective as rescue therapy...
  7. ncbi Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease?
    G T Ho
    University Department of Medical Sciences, Western General Hospital, Edinburgh, UK
    Gut 52:759-66. 2003
    ..Current studies promise to provide further insights into the contribution of the MDR1 gene in the pathogenesis of inflammatory and malignant disorders of the gastrointestinal tract...
  8. ncbi Regional variation in gene expression in the healthy colon is dysregulated in ulcerative colitis
    C L Noble
    Gastrointestinal Unit, Molecular Medicine Centre, Western General Hospital, Edinburgh, EH4 2XU, UK
    Gut 57:1398-405. 2008
    ..To investigate differential intestinal gene expression in patients with ulcerative colitis and in controls...
  9. ncbi The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up
    C W Lees
    Gastrointestinal Unit, Western General Hospital, Edinburgh, UK
    Aliment Pharmacol Ther 29:286-97. 2009
    ..Anti-TNF agents are now widely used in Crohn's disease (CD), and in ulcerative colitis (UC)...
  10. ncbi Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery
    G T Ho
    University Department of Gastroenterology, Western General Hospital, Edinburgh EH4 2XU, Scotland, UK
    Aliment Pharmacol Ther 19:1079-87. 2004
    ..A risk index, to aid the identification of patients of not responding at an early stage to intravenous corticosteroid therapy, would be useful to facilitate second-line treatment or surgery...
  11. ncbi Outcomes of the rectal remnant following colectomy for ulcerative colitis
    R R W Brady
    Academic Coloproctology, University of Edinburgh, Western General Hospital, Edinburgh, UK
    Colorectal Dis 10:144-50. 2008
    ..This study reviews the clinical outcomes of patients who have undergone colectomy for UC with intra-peritoneal closure of the rectal remnant...
  12. ncbi Lack of association of the pregnane X receptor (PXR/NR1I2) gene with inflammatory bowel disease: parallel allelic association study and gene wide haplotype analysis
    G-T Ho
    Gut 55:1676-7. 2006
  13. ncbi Toll-like receptor 4 gene in IBD: further evidence for genetic heterogeneity in Europe
    I D R Arnott
    Gut 54:308; author reply 309. 2005